Advanced Search

Home Health & Hospice Week

Industry Note:

Pneumococcal Vaccine May Get More Effective For Elderly

Published on Thu Oct 18, 2012

Your patients may receive better protection against pneumonia in the future, depending on the outcome of a National Institutes of Health-funded study. Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases. The trial will enroll up to 882 men and women ages 55 to 74.A randomized clinical trial will test and compare three groups of patients, NIH says in a release; those who received the old vaccine (PPSV23 -- Pneumovax 23) three to seven years ago and a new lower dose of PPSV13 (Prevnar 13), those who received Pneumovax 23 three to seven years ago and a new higher dose of Prevnar 13, and those who did not receive Pneumovax 23, just the new lower dose of Prevnar 13."Earlier studies suggest that PCV13 may not induce as strong [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Home Health & Hospice Week

View All